PhosSight: A Unified Deep Learning Framework Boosting and Accelerating Phosphoproteome Identification to Enable Biological Discoveries
Ben Wang, Zhiyuan Cheng, Chengying She, Hongwei Zhao, Jiahui Zhang, Lin Lv, Zhihao Yan, Hongwen Zhu, Lizhuang Liu, Yan Fu, Xinpei Yi
Journal:Advanced Science
IF:14.1
DOI:10.1002/advs.75856
PMID:
Published:2026-05-27
research field:蛋白质组学生物信息学机器学习计算生物学分子肿瘤学信号转导质谱技术
Abstract
Protein phosphorylation is a key regulator of signaling, with mass spectrometry (MS) based phosphoproteomics serving as the premier technology for its analysis. However, phosphorylation profiling is hindered by acquisition biases: Data-Dependent Acquisition (DDA) suffers from stochastic undersampling and missing values, while Data-Independent Acquisition (DIA) faces computational bottlenecks and inefficiencies from vast spectral libraries. We present PhosSight, a unified deep learning framework designed to augment identification depth and accelerate search efficiency. PhosSight features PhosDetect, a model that explicitly encodes phosphorylation-specific physicochemical features to accurately predict peptide detectability. For DDA, PhosSight leverages predicted retention time, fragment intensity, and detectability to refine site localization and rescoring, recovering marginal, low-abundance spectra. For DIA, PhosSight utilizes detectability-guided library pruning to remove non-detectable noise, accelerating search speeds without compromising sensitivity. Benchmarking on synthetic and real-world datasets confirms PhosSight's superior performance in both modes. Applying PhosSight to a large-scale Uterine Corpus Endometrial Carcinoma (UCEC) cohort improved data completeness and expanded the quantifiable phosphoproteome. This enhanced completeness enabled the discovery of novel prognosis-associated kinase targets, such as MARK2, underscoring PhosSight as a powerful tool for biological discovery in precision oncology. Trial Registration : Not applicable. This study did not prospectively assign human participants to any health-related intervention and therefore does not constitute a clinical trial requiring registration.
本文使用的Yeasen产品


